Last reviewed · How we verify
Bay F 4975 (ACEMETACIN)
Bay F 4975 (generic name: ACEMETACIN) is a acemetacin drug. It is currently in Phase 2 development for Ankylosing spondylitis, Rheumatism.
Acemetacin works by inhibiting the enzyme lactoylglutathione lyase, which is involved in the breakdown of certain inflammatory mediators.
Bay F 4975 is a small molecule inhibitor of the enzyme Cyclooxygenase. It is classified as a cyclooxygenase inhibitor, with synonyms including Acemetacin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ACEMETACIN |
|---|---|
| Drug class | acemetacin |
| Target | Lactoylglutathione lyase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Think of it like a fire alarm in a burning building. The fire alarm (lactoylglutathione lyase) is triggered by the fire (inflammation), and it sends a signal to the firefighters (other enzymes) to come and put out the fire. Acemetacin blocks the fire alarm, so the firefighters don't get the signal, and the inflammation continues to burn.
Approved indications
- Ankylosing spondylitis
- Rheumatism
Common side effects
- Axial spondyloarthritis
- Spinal osteoarthritis
- Ankylosing spondylitis
- Residual urine volume increased
- Uveitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bay F 4975 CI brief — competitive landscape report
- Bay F 4975 updates RSS · CI watch RSS
Frequently asked questions about Bay F 4975
What is Bay F 4975?
How does Bay F 4975 work?
What is Bay F 4975 used for?
What is the generic name of Bay F 4975?
What drug class is Bay F 4975 in?
What development phase is Bay F 4975 in?
What are the side effects of Bay F 4975?
What does Bay F 4975 target?
Related
- Drug class: All acemetacin drugs
- Target: All drugs targeting Lactoylglutathione lyase
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Rheumatism
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing